Cybin Inc. Announces Annual Meeting Voting Results and Advances Neuropsychiatry Pipeline

Cybin Inc. reported the results of its annual meeting of shareholders held on August 18, 2025, with significant shareholder participation demonstrating strong investor engagement. A total of 90 shareholders were represented in person or by proxy, holding 11,264,212 common shares, which accounted for 48.92% of the company's issued and outstanding common shares as of the record date. This level of participation reflects ongoing investor interest in the company's progress in developing next-generation mental healthcare treatments.

The clinical-stage neuropsychiatry company is advancing a promising pipeline of novel treatments that could address the substantial unmet needs in mental healthcare. Cybin's lead candidate, CYB003, represents a proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule undergoing Phase 2 evaluation for generalized anxiety disorder. These programs build upon promising proof-of-concept data suggesting the potential for intermittent treatments that provide long-lasting results.

Cybin's research extends beyond these clinical candidates to include a pipeline of investigational compounds focused on 5-HT receptors, indicating a comprehensive approach to neuropsychiatry drug development. The company maintains operational presence across multiple countries including Canada, the United States, the United Kingdom, the Netherlands, and Ireland, reflecting its global research and development strategy. Investors can access the latest news and updates relating to CYBN through the company's newsroom at https://ibn.fm/CYBN.

The implications of Cybin's progress extend beyond shareholder returns to potentially transformative impacts on mental healthcare. With millions worldwide suffering from treatment-resistant depression and anxiety disorders, the development of novel therapeutic approaches could address significant gaps in current treatment options. The company's focus on intermittent treatments that provide sustained benefits represents a paradigm shift from daily medication regimens, potentially improving patient adherence and quality of life. As mental health awareness continues to grow globally, successful development of these treatments could position Cybin as a leader in the evolving neuropsychiatry landscape while addressing critical public health needs.